Trial profile. *Patients were included in the safety population. †Two patients on ZOL received a conditioning regimen other than high-dose melphalan and underwent subsequent ASCT. ‡One patient in the nonintensive pathway who was excluded because no consent was received was then included in the randomization to receive maintenance treatment. Some of the 23 patients in the intensive pathway who did not start CVAD or CTD did receive high-dose melphalan plus ASCT, but none was included in the randomization to receive maintenance treatment. None of the 12 patients in the nonintensive pathway who did not start MP or CTDa was included in the randomization to receive maintenance treatment. BD indicates bortezomib and dexamethasone; CVAD, cyclophosphamide, vincristine, doxorubicin, and dexamethasone; CTD, cyclophosphamide, thalidomide, and dexamethasone; CTDa, attenuated CTD; and MP, melphalan and prednisolone. Reprinted from The Lancet, 376, Morgan GJ, Davies FE, Gregory WM, et al, First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial, 1989-1999, copyright 2010, with permission from Elsevier.¹¹